Seyedeh Hoda Alavizadeh
Overview
Explore the profile of Seyedeh Hoda Alavizadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moosavian S, Amin M, Alavizadeh S, Jaafari M, Kesharwani P, Sahebkar A
Tissue Cell
. 2025 Mar;
95:102830.
PMID: 40068280
A promising strategy for improving the effectiveness, specificity and safety of cancer treatment is targeted medication delivery. Prostate-specific membrane antigen (PSMA) is an effective biomarker for tracking and treating prostate...
2.
Hosseinikhah S, Farhoudi L, Mirzavi F, Vahdat-Lasemi F, Arabi L, Gheybi F, et al.
Eur J Pharm Sci
. 2025 Jan;
206:107024.
PMID: 39863136
Premature drug release is the primary hindrance to the effective function of the lyso-thermosensitive liposomes (LTSLs) of doxorubicin (Dox), known as ThermoDox® for the treatment of cancer. Herein, we have...
3.
Rahchamandi S, Mirhadi E, Gheybi F, Kazemi-Beydokhti A, Jaafari M, Mostafavi E, et al.
Environ Res
. 2024 Sep;
262(Pt 2):119933.
PMID: 39278586
Carbon-based nanomaterials have been frequently used as one of the most advanced and fascinating nanocarriers for drug delivery applications due to their unique physicochemical properties. Varying types of carbon nanomaterials...
4.
Aftabi S, Behrooz A, Cordani M, Rahiman N, Sadeghdoust M, Aligolighasemabadi F, et al.
FEBS J
. 2024 Jul;
PMID: 39083441
Transforming growth factor-β (TGF-β) plays a complex role in lung cancer pathophysiology, initially acting as a tumor suppressor by inhibiting early-stage tumor growth. However, its role evolves in the advanced...
5.
Khabbazian S, Mirhadi E, Gheybi F, Askarizadeh A, Jaafari M, Alavizadeh S
Colloids Surf B Biointerfaces
. 2024 Jul;
242:114085.
PMID: 39018910
Cisplatin is a widely-used chemotherapeutic agent for the treatment of various solid neoplasms including colon cancer. Cisplatin-induced DNA damage is restricted due to dose-related adverse reactions as well as primary...
6.
Khoshkhabar R, Yazdani M, Alavizadeh S, Saberi Z, Arabi L, Jaafari M
Int Immunopharmacol
. 2024 Jun;
137:112437.
PMID: 38870880
The over-activation of tryptophan (Trp) metabolism to kynurenine (Kyn) catalyzed by Indoleamine 2,3-dioxygenase-1 (IDO1) enzyme, is one of the main metabolic pathways involved in tumor microenvironment (TME) immune escape and...
7.
Moghadam S, Ebrahimpour M, Alavizadeh S, Kesharwani P, Sahebkar A
Bioorg Med Chem Lett
. 2024 Apr;
106:129762.
PMID: 38649117
Lipids play an important role in varying vital cellular processes including cell growth and division. Elevated levels of low-density lipoprotein (LDL) and oxidized-LDL (ox-LDL), and overexpression of the corresponding receptors...
8.
Mirhadi E, Askarizadeh A, Farhoudi L, Mashreghi M, Behboodifar S, Alavizadeh S, et al.
Chem Phys Lipids
. 2024 Apr;
261:105396.
PMID: 38621603
In this study, we have developed a redox-sensitive (RS) liposomal doxorubicin formulation by incorporating 10,10'-diselanediylbis decanoic acid (DDA) organoselenium compound as the RS moiety. Hence, several RS liposomal formulations were...
9.
Doagooyan M, Alavizadeh S, Sahebkar A, Houshangi K, Khoddamipour Z, Gheybi F
Int J Pharm X
. 2023 Nov;
6:100214.
PMID: 38024450
Combination therapy represents a promising strategy in cancer management by reducing chemotherapy resistance and associated side effects. Silymarin (SLM) has been extensively investigated due to its potent antioxidant properties and...
10.
Rahiman N, Zamani P, Arabi L, Alavizadeh S, Nikpoor A, Mashreghi M, et al.
Int J Pharm
. 2023 Nov;
648:123620.
PMID: 37981250
The frequent administration rate required for Glatiramer acetate (GA), a first-line therapy for Multiple sclerosis (MS), poses patient compliance issues. Only a small portion of the subcutaneously administered GA is...